Effect of Indomethacin on the Progression of Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00432081|
Recruitment Status : Completed
First Posted : February 6, 2007
Last Update Posted : February 6, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: indomethacin||Phase 3|
Previous research indicates that inflammation plays a role in the pathogenesis of Alzheimer’s disease (AD), and nonsteroidal anti-inflammatory drugs (NSAIDs) may retard the progression of the disease.
Comparison(s): Cognitive decline of patients with mild to moderate AD receiving the NSAID indomethacin, compared to cognitive decline of patients with mild to moderate AD receiving placebo, during a one-year period.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effect of Indomethacin on the Progression of Alzheimer's Disease|
|Study Start Date :||May 2000|
|Estimated Study Completion Date :||August 2005|
U.S. FDA Resources
- Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.
- Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months
- Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months
- Score on the Mini-Mental State Examination at 12 months
- Score on the Neuropsychiatric Inventory at 12 months
- Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months
- The occurrence of adverse events during 12 months of treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00432081
|Arnhem, Netherlands, 6800 TA|
|Radboud University Medical Center|
|Nijmegen, Netherlands, 6500 HB|
|Principal Investigator:||Rene WM Jansen, MD, PhD||Radboud University Medical Center Nijmegen|
|Principal Investigator:||Berry PH Kremer, MD, PhD||Radboud University Medical Center Nijmegen|
|Study Director:||Danielle De Jong, MD||Radboud University Medical Center Nijmegen|